[en] The dopamine theory of migraine pathogenesis, first proposed by F. Sicuteri in 1977, has attracted renewed interest after an increased frequency of the dopamine D2 receptor (DRD2) gene allele NcoI C was found in patients with migraine with aura.
Disciplines :
Neurology Neurosciences & behavior
Author, co-author :
Mascia, A.
Afra, J.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Language :
English
Title :
Dopamine and Migraine: A Review of Pharmacological, Biochemical, Neurophysiological, and Therapeutic Data
Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991;31:282-90
Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13:151-65
Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996;46:1404-9
Sicuteri F. Dopamine, the second putative protagonist in headache. Headache 1977;17:129-31
Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology 1997;49:201-6
Del Zompo M, Cherchi A, Ponti M, Lai M, Piccardi MP. Association study between dopamine D2, D3 and D4 receptor genes and migraine without aura in a Sardinian sample. Cephalalgia 1997;17:329
Hyde TM, Knable MB, Murray AM. Distribution of dopamine D1-D4 receptor subtypes in human dorsal vagal complex. Synapse 1996;24:224-32
Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 1983;89:137-41
Sicuteri F, Bonucci M, Cangi F, Pietrini U, Fanciullacci M. Syncope and dopamine-receptor hyperreactivity: myths and facts about basilar artery migraine. In: Carroll JD, Pfaffenrath V, Sjaastad O, editors. Migraine and beta-blockade. Molndal: Hassle AB, 1985:147-60
Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995;60:3-38
Paalzow GHM. 1-Dopa induces opposing effects on pain in intact rats: (-)-sulpiride, SCH 23390 or alpha-methyl-DL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses. J Pharmacol Exp Ther 1992;263:470-9
Miley DP, Abrams AA, Atkinson JH, Janowsky DS. Successful treatment of thalamic pain with apomorphine. Am J Psychiatry 1978;135:1230
Grant R, Behan PO. Resistant thalamic pain treated by levodopa. Br Med J 1984;289:1272
Kernbaum S, Hauchecorne J. Administration of levodopa for relief of herpes zoster pain. J Am Med Assoc 1981;246:132-4
Nutt JG, Carter JH. Sensory symptoms in Parkinsonism related to central dopaminergic function. Lancet 1984;ii:456-7
Lorentz IT. A survey of headache in Parkinson's disease. Cephalalgia 1989;9:83-6
Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg 1992; Suppl 94:168-70
Sabatini U, Rascol O, Rascol A, Montastruc J. Migraine attacks induced by subcutaneous apomorphine in two migrainous Parkinsonian patients. Clin Neuropharmacol 1990;13:264-7
Guan XM, McBride WJ. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 1989;23:541-7
Boulenguez P, Rawlins JN, Chauveau J, Joseph MH, Mitchell SN, Gray JA. Modulation of dopamine release in the nucleus accumbens by 5HT1B agonists: involvement of the hippocampo-accumbens pathway. Neuropharmacology 1996;35: 1521-5
Nissbrandt H, Waters N, Hjorth S. The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol 1992;346:12-9
Saito H, Matsumoto M, Togashi H, Yoshioka M. Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Jpn J Pharmacol 1996;70:203-5
Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G. Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991;14:91-5
Del Bene E, Poggioni M, De Tommasi F. Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 1994;34:536-8
Del Zompo M, Lai M, Loi V, Pisano MR. Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache 1995;35:222-4
Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, Roberti C, et al. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 1997;20:36-41
Fanciullacci M, Michelacci S, Curradi C, Sicuteri F. Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 1980;20:99-102
Serra G, Collu M, Gessa GL. Yawning is elicited by D2 dopamine agonists but is blocked by D1 antagonists, SCH 23390. Psychopharmacology 1987;91:330-3
Bès A, Comet B, Dupui P, Guell A, Arne-Bès MC, Géraud G. Antimigraine drugs and dopamine hypersensitivity. In: Amery WK, Van Nueten JM, Wauquier A, editors. The pharmacological basis of migraine therapy. London: Pitman Press, 1984:202-12
Calabresi P, Silvestrini M, Stratta F, Cupini LM, Arigo G, Atzei GP, et al. 1-Deprenyl test in migraine: neuroendocrinological aspects. Cephalalgia 1993;13:406-9
International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96
Pradalier A, Launay JM, Dry J, Dreux C, Artigou C. Migraine commune. Variations des catécholamines conjuguées et non conjuguées. Presse Med 1985;14:583-5
D'Andrea G, Welch KMA, Nagel-Leiby S, Grunfeld S, Joseph R. Platelet catecholamines in migraine. Cephalalgia 1989;9:3-5
Nagel-Leiby S, Welch KMA, D'Andrea G, Grunfeld S, Brown E. Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia 1990;10:317-29
Kovács K, Bors L, Tóthfalusi L, Jelencsik I, Bozsik Gy, Kerényi L, et al. Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia 1989;9:53-7
Castillo J, Martinez F, Suarez C, Naveiro J, Lema M, Noya M. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia 1996;16: 56-61
Barbanti P, Bronzetti E, Ricci A, Cerbo R, Fabbrini G, Buzzi MG, et al. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci Lett 1996;207:73-6
Timsit-Berthier M, Mantanus H, Marissiaux P, Ansseau M, Doumont A, Geenen V, et al. CNV and dopamine receptor reactivity: correlations with the apomorphine test. Electroencephalogr Clin Neurophysiol Suppl 1986;38:403-5
Schoenen J, Maertens de Noordhout A, Timsit-Berthier M, Timsit M. Contingent negative variation (CNV) as a diagnostic and physiopathologic tool in headache patients. In: Clifford Rose, editor. Migraine. Proc 5th Int Migraine Symp, London 1984. Basel: Karger, 1985:17-25
Lenarduzzi P, Timsit-Berthier M, Gérard P, Schoenen J. Variation contingent negative (VCN) dans la migraine avec aura ("migraine classique") en période intercritique. Société Française d'études des migraines et céphalées. Association pour la Neuro-psyco-pharmacologie 1988:17-8
Böcker KBE, Timsit-Berthier M, Schoenen J, Brunia CHM. Contingent negative variation in migraine. Headache 1990;30:604-9
Kropp P, Gerber WD. Contingent negative variation - findings and perspectives in migraine. Cephalalgia 1993;13:33-6
Kropp P, Gerber WD. The predictable migraine attack. News in Headache 1994;4:3
Kropp P, Gerber WD. Contingent negative variation during migraine attack and interval: evidence for normalization of slow cortical potentials during the attack. Cephalalgia 1995;15:123-8
Kropp P, Gerber WD, Repas V. Can migraine attacks be predicted by evaluation of contingent negative variation? Cephalalgia 1997;17:266
Schoenen J, Wang W, Albert A, Delwaide PJ. Potentiation instead of habituation characterizes visual evoked potentials in migraine patients between attacks. Eur J Neurol 1995;2:115-22
Áfra J, Proietti Cecchini A, De Pasqua V, Albert A, Schoenen J. Visual evoked potentials during long-lasting pattern-reversal stimulations in migraine. Brain 1997 (in press)
Wang W, Schoenen J, Timsit-Berthier M. Cognitive functions in migraine without aura between attacks: a psychophysiological approach using the "oddball" paradigm. Neurophysiologie Clinique 1995;25:3-11
Evers S, Bauer B, Suhr B, Husstedt IW, Grotemeyer KH. Cognitive processing in primary headache: a study on event-related potentials. Neurology 1997;48:108-13
Onofrj M, Bodis-Wollner I. Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann Neurol 1982; 11:484-90
Yamamoto K, Hagino K, Moroji T, Ishii T. Habituation failure of skin conductance response after intraventricular administration of 6-hydroxydopamine in cats. Experimentia 1984;40: 344-5
Imperato A, Cabib S, Puglisi-Allegra S. Repeated stressful experiences differently affect the time-dependent responses of the mesolimbic dopamine system to the stressor. Brain Res 1993;601:333-6
Volans GN. The effect of the metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975;2:57-63
Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983;24:277-85
Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 1988;8:139-47
Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combination in the treatment of migraine attacks. Cephalalgia 1984;4:253-63
McGregor A, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993;13:124-7
Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984;4:107-11
Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the Emergency Department. Ann Emerg Med 1990;19:1083-7
Hughes JB. Metoclopramide in migraine treatment [Letter]. Med J Aust 1977;2:580
Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5
Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs metoclopramide in acute migraine headache. Acad Emerg Med 1995;2:597-602
Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-6
Hakkarainen H, Allonen H. Ergotamine vs metoclopramide vs their combination in acute migraine attacks. Headache 1982;22:10-12
Amery WY, Waelkens J. Prevention of the last chance: an alternative pharmacological treatment of migraine. Headache 1983;23:37-8
McEwen JI, O'Connor HM, Dinsdale HB. Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med 1987;16:758-63
Iserson KV. Parenteral chlorpromazine treatment of migraine. Ann Emerg Med 1983;12:756-8
Lane RL, Ross R. Intravenous chlorpromazine - preliminary results in acute migraine. Headache 1985;25:302-4
Bell R, Motoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990;19:1079-82
Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261:1174-6
Fisher H. A new approach to emergency department therapy of migraine headache with intravenous haloperidol: a case series. J Emerg Med 1995;13:119-22
Lugaresi A, Montagna P, Gallasi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol 1988;28:208-11
Piccini P, Nuti A, Paoletti AM, Napolitano A, Melis GB, Bonuccelli U. Possible involvement of dopaminergic mechanisms in the antimigraine action of flunarizine. Cephalalgia 1990;10:3-8
Wöber C, Brücke T, Wöber-Bingöl C, Asenbaum S, Wessely P, Podreka I. Dopamine D2-receptor blockade and antimigraine action of flunarizine. Cephalalgia 1994;14:135-40
Louis P. A double-blind placebo controlled prophylactic study of flunarizine (Sibelium®) in migraine. Headache 1981;21:235-9
Cerbo R, Casacchia M, Formisano R, Feliciani M, Cusimano G, Buzzi MG, et al. Flunarizine-pizotifen single dose, double-blind cross-over trial in migraine prophylaxis. Cephalalgia 1986;6:15-8
Lucking HC, Oestreich W, Schmidt R, Soyka D. Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 1988; Suppl 8:21-6
Soyka D, Taneri Z, Oestreich W, Schmidt R. Flunarizine i.v. in the acute treatment of common or classical migraine attacks a placebo-controlled double blind trial. Headache 1989;29:21-7
Pfaffenrath V, Oestreich W, Haase W. Flunarizine (10 and 20 mg) i.v. versus placebo in the treatment of acute migraine attacks: a multi-centre double-blind study. Cephalalgia 1990;10:77-81
Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6
Andersch B, Hahn L, Wendestam C, Ohman R, Abrahamsson L. Treatment of premenstrual syndrome with bromocriptine. Acta Endocrinol 1978;88 Suppl 216:165-74
Andersen AN, Larsen JF, Steenstrup OR, Svendstrup B, Nielsen J. Effect of bromocriptine on the premenstrual syndrome: a double-blind clinical trial. Br J Obstet Gynaecol 1977;84:370-4
Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology 1997;48:101-2
Herrmann WM, Horowsky R, Dannehl K, Kramer U, Lurati K. Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide. Headache 1977;17:54-60
Sommerville BW, Herrmann WM. Migraine prophylaxis with lisuride hydrogen maleate double-blind study of lisuride versus placebo. Headache 1978;18:75-9
Sances G, Martignoni M, Rosettino G, Fioroni L, Montorsi S, Runge I, et al. Lisuride in menstrual migraine prophylaxis. Cephalalgia 1989;9 Suppl 10:444-5
Nattero G, Biale L, Savi L. Lisuride and pizotifen in the treatment of migraine without aura. Cephalalgia 1991; Suppl 11:217-9
Canonico PL, Scapagnini U, Genazzani E, Zanotti A. Dihydroergokryptine (DEK) in the prophylaxis of common migraine: double-blind clinical study vs placebo. Cephalalgia 1989;9 Suppl 10:445-7
Avella F, Poli A, Ambrosoli L, Girardello R. The effectiveness of α-dihydroergocryptine in migraine prophylaxis: a double-blind clinical study vs placebo. Cephalalgia 1997;17:435
Frediani F, Grazzi L, Zanotti A, Mailland F, Zappacosta BM, Bussone G. Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial. Cephalalgia 1991;11:117-21
Peroutka SJ. Dopamine and migraine. Neurology 1997;49:650-6
Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984;4:85-90
Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ. Interaction of neurotransmitter system. A non-experimental approach to 5-HIAA-HVA correlation in human CSF. J Psychiatr Res 1986;20:175-93
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-52
Terwindt GM, Ophoff RA, Sandkuijl LA, van Eijk R, Haan J, Frants RR, et al. Involvement of the familial hemiplegic migraine gene on 19p13 in migraine with and without aura. Cephalalgia 1997;17:232
Codignola A, Tarroni P, Clementi F, Polio A, Lovallo M, Carbone E, et al. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J Biol Chem 1993;268:26240-7
Coming DE, Coming BG, Muhleman D, Dietz G, Shahbahrami B, Tast D, et al. The Dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991;266:1793-800
Noble EP. The gene that rewards alcoholism. Sci Med 1996;3:52-61
Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritche T, Jagadeeswaran P, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990;263:2055-60
Bolos AM, Dean M, Lucas-Derse S, Ramsburg M, Brown GL, Goldman D. Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA 1990;264:3156-60
Gejman PV, Ram A, Gelernter J. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. JAMA 1994;271:204-8
Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicenter double-blind placebo-controlled study. Cephalalgia 1994;14:297-300
